These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 37857905)

  • 1. Safety and efficacy of sodium zirconium cyclosilicate for the management of acute and chronic hyperkalemia in children with chronic kidney disease 4-5 and on dialysis.
    Khandelwal P; Shah S; McAlister L; Cleghorn S; King L; Shroff R
    Pediatr Nephrol; 2024 Apr; 39(4):1213-1219. PubMed ID: 37857905
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects and Safety of a Novel Oral Potassium-Lowering Drug-Sodium Zirconium Cyclosilicate for the Treatment of Hyperkalemia: a Systematic Review and Meta-Analysis.
    Zhang Y; Xu R; Wang F; Liu Y; Xu J; Zhao N; Cheng F; Long L; Jia J; Lin S
    Cardiovasc Drugs Ther; 2021 Oct; 35(5):1057-1066. PubMed ID: 33459923
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of effectiveness and safety of sodium polystyrene sulfonate and sodium zirconium cyclosilicate for treatment of hyperkalemia in hospitalized patients.
    Sullivan E; Ruegger M; Dunne I; Sutaria N; Towers WF
    Am J Health Syst Pharm; 2023 Sep; 80(18):1238-1246. PubMed ID: 37335862
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potassium-lowering effects of sodium zirconium cyclosilicate in the early post-transplant period.
    Shockey W; Wiegel JJ; Parajuli S; Garg N; Swanson KJ; Mandelbrot DA
    Clin Transplant; 2024 Jan; 38(1):e15156. PubMed ID: 37812572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Phase 3b, Randomized, Double-Blind, Placebo-Controlled Study of Sodium Zirconium Cyclosilicate for Reducing the Incidence of Predialysis Hyperkalemia.
    Fishbane S; Ford M; Fukagawa M; McCafferty K; Rastogi A; Spinowitz B; Staroselskiy K; Vishnevskiy K; Lisovskaja V; Al-Shurbaji A; Guzman N; Bhandari S
    J Am Soc Nephrol; 2019 Sep; 30(9):1723-1733. PubMed ID: 31201218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of sodium zirconium cyclosilicate on acid-base balance in chronic kidney disease.
    Mori D; Namiki Y; Sugimachi A; Kado M; Tamai S; Nomi H; Haga R; Nagatoya K; Yamauchi A
    Clin Nephrol; 2022 May; 97(5):255-260. PubMed ID: 34958299
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potassium binders for chronic hyperkalaemia in people with chronic kidney disease.
    Natale P; Palmer SC; Ruospo M; Saglimbene VM; Strippoli GF
    Cochrane Database Syst Rev; 2020 Jun; 6(6):CD013165. PubMed ID: 32588430
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of hyperkalemia in chronic heart failure using sodium zirconium cyclosilicate.
    Oshima A; Imamura T; Narang N; Kinugawa K
    Clin Cardiol; 2021 Sep; 44(9):1272-1275. PubMed ID: 34263946
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DIALIZE China: A Phase IIIb, Randomized, Placebo-Controlled Study to Reduce Predialysis Hyperkalemia With Sodium Zirconium Cyclosilicate in Chinese Patients.
    Ni Z; Lu R; Xu X; Bian X; Zhou Z; Yang J; Luo Q; Chen M; Chen C; Sun X; Yu L; He Q; Jiang H; Yuan W; Li Y; Zhou R; Wang J; Zhang X; Zuo L; Meng X; Chang Z; Zhao J; Wessman P; Xiang P;
    Clin Ther; 2023 Jul; 45(7):633-642. PubMed ID: 37385905
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term safety and efficacy of sodium zirconium cyclosilicate for hyperkalaemia in patients with mild/moderate versus severe/end-stage chronic kidney disease: comparative results from an open-label, Phase 3 study.
    Roger SD; Lavin PT; Lerma EV; McCullough PA; Butler J; Spinowitz BS; von Haehling S; Kosiborod M; Zhao J; Fishbane S; Packham DK
    Nephrol Dial Transplant; 2021 Jan; 36(1):137-150. PubMed ID: 32030422
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of Patiromer and Sodium Zirconium Cyclosilicate on Blood Pressure in Rats with Chronic Kidney Disease.
    Li L; Budden J; Quinn CM; Bushinsky D
    J Cardiovasc Pharmacol Ther; 2024; 29():10742484241227580. PubMed ID: 38311939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An evaluation of sodium zirconium cyclosilicate as a treatment option for hyperkalemia.
    Takkar C; Nassar T; Qunibi W
    Expert Opin Pharmacother; 2021 Jan; 22(1):19-28. PubMed ID: 32892634
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sodium zirconium cyclosilicate increases serum bicarbonate concentrations among patients with hyperkalaemia: exploratory analyses from three randomized, multi-dose, placebo-controlled trials.
    Roger SD; Spinowitz BS; Lerma EV; Fishbane S; Ash SR; Martins JG; Quinn CM; Packham DK
    Nephrol Dial Transplant; 2021 Apr; 36(5):871-883. PubMed ID: 32588050
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness analysis of sodium zirconium cyclosilicate for hyperkalemia among patients with chronic kidney disease or heart failure in Kuwait.
    Elsisi GH; Mahmoud MMI; Al-Humood K; Al-Yousef A
    J Med Econ; 2024; 27(1):253-265. PubMed ID: 38318718
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potassium responses to sodium zirconium cyclosilicate in hyperkalemic hemodialysis patients: post-hoc analysis of DIALIZE.
    Fishbane S; Ford M; Fukagawa M; McCafferty K; Rastogi A; Spinowitz B; Staroselskiy K; Vishnevskiy K; Lisovskaja V; Al-Shurbaji A; Guzman N; Bhandari S
    BMC Nephrol; 2022 Feb; 23(1):59. PubMed ID: 35135481
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Sodium Zirconium Cyclosilicate on Serum Potassium and Bicarbonate in Patients with Hyperkalemia and Metabolic Acidosis Associated with Chronic Kidney Disease: Rationale and Design of the NEUTRALIZE Study.
    Ash SR; Batlle D; Kendrick J; Oluwatosin Y; Pottorf W; Brahmbhatt Y; Guerrieri E; Fried L
    Nephron; 2022; 146(6):599-609. PubMed ID: 35462371
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sodium zirconium cyclosilicate for the management of chronic hyperkalemia in kidney disease, a novel agent.
    Rastogi A; Hanna RM; Mkrttchyan A; Khalid M; Yaqoob S; Shaffer K; Dhawan P; Nobakht N; Kamgar M; Goshtaseb R; Sarmosyan K; Gnarini M; Wassef O; Lerma E
    Expert Rev Clin Pharmacol; 2021 Sep; 14(9):1055-1064. PubMed ID: 34227913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plant-based diet in hyperkalemic chronic kidney disease patients receiving sodium zirconium cyclosilicate: A feasibility clinical trial.
    Avesani CM; Heimbürger O; Rubin C; Sallstrom T; Fáxen-Irving G; Lindholm B; Stenvinkel P
    Am J Clin Nutr; 2024 Jul; ():. PubMed ID: 39032787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum potassium response to single-dose sodium zirconium cyclosilicate for the treatment of asymptomatic hyperkalemia in hospitalized patients.
    Lewis H; Stamper B; Yungkurth AC
    Pharmacotherapy; 2024 Jan; 44(1):13-21. PubMed ID: 37475499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single Dose of Sodium Zirconium Cyclosilicate Versus Sodium Polystyrene Sulfonate in Hospitalized Patients With Hyperkalemia.
    Yoo N; Song YB; Dubinsky I; Altshuler J
    Ann Pharmacother; 2023 Sep; 57(9):1044-1052. PubMed ID: 36637028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.